Results 1 to 10 of about 28,438 (118)

Evolutionary information helps understand distinctive features of the angiotensin II receptors AT1 and AT2 in amniota.

PLoS Computational Biology, 2022
In vertebrates, the octopeptide angiotensin II (AngII) is an important in vivo regulator of the cardiovascular system. It acts mainly through two G protein-coupled receptors, AT1 and AT2.
Rym Ben Boubaker, Asma Tiss, Daniel Henrion, Hajer Guissouma, Marie Chabbert   +4 more
doaj   +2 more sources

Maternal treatment with agonistic autoantibodies against type-1 angiotensin II receptor in late pregnancy increases apoptosis of myocardial cells and myocardial susceptibility to ischemia-reperfusion injury in offspring rats. [PDF]

PLoS ONE, 2013
Epidemiological studies have demonstrated that offspring born to mothers preeclampsia (PE) are at increased risk for developing cardiovascular diseases after birth, but the underlying mechanism is unknown. Angiotensin II receptor type 1 autoantibody (AT1-
Zhu Jin, Wenhui Zhang, Hailiang Yang, Xiaofang Wang, Yanqian Zheng, Qiaoyan Zhang, Jianming Zhi   +6 more
doaj   +1 more source

Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers. [PDF]

PLoS ONE, 2013
While the molecular structures of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are very similar, they are also slightly different. Although each ARB has been shown to exhibit a unique mode of binding to AT1 receptor, different positions ...
Shin-Ichiro Miura, Naoki Nakao, Hiroyuki Hanzawa, Yoshino Matsuo, Keijiro Saku, Sadashiva S Karnik   +5 more
doaj   +1 more source

Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma

Cell Reports, 2023
Summary: Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer and presents clinically with a high degree of biological heterogeneity and distinct clinical outcomes.
Minxiao Yang, Hua Shen, Per Flodby, Michael D. Koss, Rania Bassiouni, Yixin Liu, Tea Jashashvili, Aaron Neely, Ezuka Ogbolu, Jonathan Castillo, Theresa Ryan Stueve, Daniel J. Mullen, Amy L. Ryan, John Carpten, Alessandra Castaldi, W. Dean Wallace, Beiyun Zhou, Zea Borok, Crystal N. Marconett   +18 more
doaj   +1 more source

Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery.

PLoS ONE, 2021
Congestive heart failure, a prominent cardiovascular disease results primarily from myocardial infarction or ischemia. Milrinone (MRN), a widely used clinical drug for heart failure, improves myocardial contractility and cardiac function through its ...
Nikita Lomis, Susan Westfall, Dominique Shum-Tim, Satya Prakash   +3 more
doaj   +1 more source

RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane

Scientific Reports, 2021
The receptor for advanced glycation end-products (RAGE) and the G protein-coupled angiotensin II (AngII) type I receptor (AT1) play a central role in cardiovascular diseases.
Serina Yokoyama, Tatsuo Kawai, Koichi Yamamoto, Huang Yibin, Hiroko Yamamoto, Akemi Kakino, Hikari Takeshita, Yoichi Nozato, Taku Fujimoto, Kazuhiro Hongyo, Toshimasa Takahashi, Futoshi Nakagami, Hiroshi Akasaka, Yoichi Takami, Yasushi Takeya, Ken Sugimoto, Tatsuya Sawamura, Hiromi Rakugi   +17 more
doaj   +1 more source

Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia

Journal of Neuroinflammation, 2020
Background/aims The renin-angiotensin system (RAS) is altered in Parkinson’s disease (PD), a disease due to substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa, leads to dyskinesias as the main side ...
Rafael Rivas-Santisteban, Ana I. Rodriguez-Perez, Ana Muñoz, Irene Reyes-Resina, José Luis Labandeira-García, Gemma Navarro, Rafael Franco   +6 more
doaj   +1 more source

Large‐Conductance Calcium‐Activated Potassium Channel Opener, NS1619, Protects Against Mesenteric Artery Remodeling Induced by Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Agonistic autoantibodies against the angiotensin II type 1 receptor (AT1‐AAs) extensively exist in patients with hypertensive diseases and have been demonstrated to play crucial roles in the pathophysiological process of vascular remodeling ...
Meili Wang, Xiaochen Yin, Shuanglei Li, Xi Zhang, Ming Yi, Chunyu He, Xiaoyue Li, Wei Wang, Suli Zhang, Huirong Liu   +9 more
doaj   +1 more source

Preparation and Biological Activity of the Monoclonal Antibody against the Second Extracellular Loop of the Angiotensin II Type 1 Receptor

Journal of Immunology Research, 2016
The current study was to prepare a mouse-derived antibody against the angiotensin II type 1 receptor (AT1-mAb) based on monoclonal antibody technology, to provide a foundation for research on AT1-AA-positive diseases.
Mingming Wei, Chengrui Zhao, Suli Zhang, Li Wang, Huirong Liu, Xinliang Ma   +5 more
doaj   +1 more source

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

npj Parkinson's Disease, 2022
The role of autoimmunity in neurodegeneration has been increasingly suggested. The renin-angiotensin system (RAS) autoantibodies play a major role in several peripheral inflammatory processes.
Carmen M. Labandeira, Maria A. Pedrosa, Aloia Quijano, Rita Valenzuela, Pablo Garrido-Gil, Mariña Sanchez-Andrade, Juan A. Suarez-Quintanilla, Ana I. Rodriguez-Perez, Jose L. Labandeira-Garcia   +8 more
doaj   +1 more source